Here’s a hard pill to swallow: Medicare Part B premiums are set to soar by nearly 10 percent in 2026, leaving millions of seniors and disabled enrollees facing higher healthcare costs. But here’s where it gets controversial—while the Centers for Medicare and Medicaid Services (CMS) claims this increase could have been even steeper without their intervention, critics argue it’s yet another blow to Americans already struggling with rising expenses. Let’s break it down.
Starting in 2026, the monthly actuarial rates for Medicare Part B beneficiaries will jump to $405.40 for seniors and $585.60 for disabled enrollees. To put it in perspective, the 2026 premium is $17.90 higher than the 2025 rate of $185.00, bringing the total to $202.90. And this is the part most people miss—this hike is nearly double the percentage increase seen in 2025, when premiums rose from $174.70 in 2024 to $185.00. The deductible for all Part B enrollees will also climb to $283 next year.
Medicare Part B covers essential services like ambulance rides, outpatient hospital care, certain prescription drugs, medical equipment, oxygen supplies, and treatment for substance use disorders. So, why the sudden spike? CMS points to projected price changes and increased utilization, but there’s a bigger story here.
Earlier this year, the Trump administration took aim at skin substitutes—biologic or synthetic products used for outpatient wound care. CMS data revealed that spending on these products skyrocketed from $256 million in 2019 to a staggering $10 billion in 2024. In July, the agency proposed measures to curb what it called “waste and unnecessary use” of skin substitutes. The Department of Health and Human Services Office of Inspector General even flagged these products as ripe for fraudulent billing schemes.
CMS claims that without their intervention on skin substitutes, the Part B premium increase would have been $11 more per month. They also assert that spending on these products is expected to drop by 90% under the 2026 Physician Fee Schedule Final Rule—without compromising patient care. But is this enough to justify the hike?
Rep. Richard Neal (D-Mass.), ranking member of the House Ways and Means Committee, isn’t buying it. He slammed the increase as part of the Trump administration’s “endless assault on people’s wallets and the public health system.” Neal argues that these hikes, coupled with rising costs for employer-covered Americans, are squeezing families from all sides.
Here’s the burning question: Is this a necessary adjustment to control spending, or is it another example of shifting costs onto those who can least afford it? Let us know what you think in the comments. One thing’s for sure—this debate is far from over.
